Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease
Ofer Levy, Arie Apel, Hossam Alhdor, Avraham Mizrachi, Nancy Agmon‐Levin, Maya Koren‐Michowitz, Mirit Amit-Vazina
Abstract
Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still’s disease. This is a nearly fatal case of a young patient, which has been refractory to corticoste- roids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still’s disease. Cite this article as: Levy O, Apel A, Alhdor H, et al. Ruxolitinib for refractory macrophage activation syndrome complicating adult-onset still’s disease. Eur J Rheumatol. 2022;9(4):217-220.